News | September 04, 2014

Frost & Sullivan Recognizes Volpara for Identifying Importance of Dose Tracking and Quantitative Analytics in Early Breast Cancer Detection

Frost & Sullivan Recognizes Volpara for Identifying Importance of Dose Tracking and Quantitative Analytics in Early Breast Cancer Detection

September 4, 2014 — Based on its recent analysis of the breast imaging solutions market, Frost & Sullivan recognized Volpara Solutions with the 2014 North American Frost & Sullivan Award for Technology Innovation Leadership.

Over the past few years, Volpara has steadily introduced several new solutions and expanded its global reach to cover the United States, Europe, Asia and Australia. Volpara’s suite of quantitative solutions includes VolparaDose, VolparaDensity, VolparaAnalytics and VolparaResearch. The Density and Dose solutions are patient-specific, while the Analytics and Research solutions are clinic-wide monitoring tools.

“Frost & Sullivan lauds Volpara Solutions for continuous leadership in technology innovation, thoughtfulness in identifying the unmet need for dose tracking in breast imaging and a clear vision for what analytics can achieve in the early detection and treatment of breast cancer,” said Siddharth Sadha, research director, Advanced Medical Technologies Group, Frost & Sullivan.

“Furthermore, all of the applications are built to serve across both full-field digital mammography (FFDM) and digital tomosynthesis systems, and with multi-vendor compatibility and reproducible data. This is of high relevance in the industry, as tomosynthesis is quickly gaining currency, with 30 percent of the members of the Society of Breast Imaging in the U.S. already using it,” he said.

While several market participants offer breast density measurement tools, Frost & Sullivan confirmed Volpara Solutions is the only company with a dose measurement tool specifically for breast imaging. It is necessary to measure volumetric breast density to control the dose, and Volpara Solutions emerged as a pioneer in leveraging the mega-trend of dose reduction by acknowledging patient-specific dose tracking and reporting as a white-space opportunity.

“We are very proud to be recognized for the innovative solutions we have brought to the breast imaging market and for our vision and commitment to address unmet needs in the detection, prevention and treatment of breast cancer,” said Ralph Highnam, Ph.D., Volpara Solutions CEO and chief scientist. “By allowing researchers across the globe to compare data to detect geographical, racial and age-related trends, we hope to take breast cancer research to the next level, which could lead to the development of predictive analytical models that will revolutionize early detection of breast cancer and save lives.”

For more information: www.frost.com

Related Content

Guerbet Partners With Imalogix on Dose Optimization With Artificial Intelligence
News | Radiation Dose Management | August 14, 2018
August 14, 2018 — Guerbet LLC USA announced a commercial partnership with Imalogix, a provider of...
Illinois Governor Approves State Breast Density Reporting Bill Into Law
News | Breast Density | August 13, 2018
Illinois Gov. Bruce Rauner approved the Illinois Breast Density Reporting Law (Public Act 100-0749) on Aug. 10, 2018...
PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
iCAD Receives FDA Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
Technology | Breast Density | August 08, 2018
iCAD announced U.S. Food and Drug Administration (FDA) clearance of its latest artificial intelligence (AI) software...
Cardiac Imaging Reveals Roots of Preeclampsia Damage in Pregnant Women
News | Women's Health | August 07, 2018
Johns Hopkins researchers say a heart imaging study of scores of pregnant women with the most severe and dangerous form...
Cardiac Monitoring a Higher Priority for High-Risk Breast Cancer Patients
News | Cardio-oncology | August 07, 2018
August 7, 2018 — While heart failure is an uncommon complication of...
Imalogix Brings Fluoroscopy Capabilities to Radiation Dose Management Platform
Technology | Radiographic Fluoroscopy (RF) | August 06, 2018
Imalogix, a provider of artificial intelligence (AI) process and workflow solutions, announced the availability of the...
Hologic Acquires Digital Specimen Radiography Company Faxitron Bioptics

VisionCT 3-D breast specimen-designated computed tomography (CT) system. Image courtesy of Faxitron Bioptics.

News | Breast Imaging | July 31, 2018
Hologic Inc. announced it has completed the acquisition of Faxitron Bioptics, a privately-held leader in digital...
Konica Minolta Hosting Lunch and Learn at 23rd Annual Mammography Meeting in Santa Fe
News | Breast Imaging | July 31, 2018
Konica Minolta Healthcare Americas Inc. will sponsor a lunch and learn featuring its Exa Mammo platform during the 23rd...
FDA Approves New Tomosynthesis Quality Control Tests for ACR Digital Mammography QC Manual
News | Mammography | July 30, 2018
The U.S. Food and Drug Administration (FDA) recently approved the American College of Radiology’s (ACR’s) amendment to...
Overlay Init